Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-05-09
2006-05-09
Solola, Taofiq (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S414000, C548S507000, C548S503000
Reexamination Certificate
active
07041697
ABSTRACT:
Compounds of the Formula I:are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa and bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.
REFERENCES:
patent: 5468767 (1995-11-01), Cipollina et al.
patent: 5607961 (1997-03-01), Cipollina et al.
patent: 6410739 (2002-06-01), Macor et al.
patent: 99/51592 (1999-10-01), None
Artigas, F., et al., “Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors,”Arch Gen Psychiatry, Mar. 1994, 51, 248-251.
Blier, P., et al., “Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression,”J. of Clinical Psychopharmacology, 1995, 15(3), 217-222.
Bundgaard, (Ed.), Design of Prodrugs,Elsevier, 1985.
Bundgaard, H., “Means to enhance penetration; Prodrugs as a means to improve the delivery of peptide drugs,”Advanced Drug Deliver Reviews, 1992, 8, 1-38.
Bundgaard,J. of Pharmaceutical Sciences, 1988, 7(285 et seq.).
Cheetham, S.C., et al., “[3H]paroxetine binding in rat frontal cortex strongly correlates with [3H] 5-HT uptake: effect of administration of various antidepressant treatments,”Neuropharmacol., 1993, 32(8), 737-743.
Eliel, E.L., Stereochemistry of Carbon Compounds,McGraw-Hill, NY, 1962.
Hall, M.D., et al., “{3H8-hydroxy-2-(Di-n-propylamino)tetralin binding to pre- and postsynaptic 5-hydroxytryptamine sites in various regions of the rat brain,”J. Neurochem, 1985, 44, 1685-1696.
Higuchi, et al. (Eds.), Prodrugs as Novel Drug Delivery Systems,American Chemical Society, 1975.
Jacques et al., Enantiomers, Racemates and Resolutions,Wiley Interscience, NY, 1981.
Krogsgaard-Larsen, et al. (Eds.), “Design and Application of Prodrugs,”Texbook of Drug Design and Development, 1991, Chap. 5, 113-191.
Lazareno, S., et al., “Pharmacological characterization of acetylcholine-stimulated [3S]-GTPγS binding mediated by human muscarinic m1-m4 receptors: antagonist studies,”Br. J. Pharmacol., 1993, 109, 1120-1127.
Perez, V., et al., “Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment,”The Lancet,m May 31, 1997, 349, 1594-1597.
Remington's Pharmaceutical Sciences, 17thEd., Gennaro, A.R. (Ed.),Mack Publishing Company, Easton, PA, 1985.
Tome, M.B., et al., “Serotonergic autoreceptor blocade in the reduction of antidepressant latency: personality variables and response to paroxetine and pindolol,”J. Affect Disord, 1997, 44, 101-109.
Tome, M.B., et al., “Paroxetine and pindolol: a randomized trial of serotonergic antoreceptor blockade in the reduction of antidepressant latency,”Int. Clin. Psychopharmacol, 1997, 12, 81-89.
Widder, et al. (Eds.), Methods in Enzymology,Academic Press, 1985, vol. 4.
Wilen, S.H., “Tables of Resolving Agents and Optical Resolutions,”Univ. of Notre Dame Press, Notre Dame, IN, E.L. Eliel (Ed.), 1972, p. 268-298.
Wilen, S.H., et al., “Strategies in optical resolutions,”Tetrahedron, 1977, 33, 2725-2736.
Evrard Deborah Ann
Shah Uresh Shantilal
Stack Gary Paul
Shiao Robert
Solola Taofiq
Woodcock & Washburn LLP
Wyeth
LandOfFree
Antidepressant cycloalkylamine derivatives of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antidepressant cycloalkylamine derivatives of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antidepressant cycloalkylamine derivatives of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3582851